CP
ENTA icon

Caligan Partners’s Enanta Pharmaceuticals ENTA Stock Holding History

Caligan Partners’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-184,826
Closed -$1.06M – 17
2024
Q4 		$1.06M Sell
184,826
-137,627
-43% -$1.32M 0.27% 14
2024
Q3 		$3.34M Sell
322,453
-720,436
-69% -$9.42M 1.06% 11
2024
Q2 		$13.5M Buy
1,042,889
+184,819
+22% +$2.49M 3.16% 9
2024
Q1 		$15M Buy
+858,070
New +$11.4M 3.96% 7

Other funds holding ENTA

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Caligan Partners's ENTA Position: Q1 2025 in Review

Caligan Partners sold out of Enanta Pharmaceuticals (ENTA) in Q1 2025, closing a stake of 184,826 shares — an estimated $1.06M sold.

Caligan Partners first reported a position in ENTA in Q1 2024 and held it in 4 quarters. The position peaked at $15M in Q1 2024. 109 funds tracked by Wall St. Rank hold ENTA as of Q1 2025.

  • Caligan Partners reported no remaining Enanta Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Caligan Partners sold 184,826 Enanta Pharmaceuticals shares in Q1 2025, an estimated $1.06M.
  • Caligan Partners first reported a position in Enanta Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Caligan Partners's Enanta Pharmaceuticals position peaked at $15M in Q1 2024.
  • 109 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2025.

Based on Caligan Partners's 13F filing for Q1 2025, filed 15 May 2025.